Breaking News, Collaborations & Alliances

Syngene Enters 10-Year Biologics Manufacturing Agreement with Zoetis

Will manufacture the drug substance for Librela, a monoclonal antibody used for treating osteoarthritis in dogs.

Author Image

By: Charlie Sternberg

Associate Editor

Syngene International Limited has signed a 10-year agreement with animal health company, Zoetis, to manufacture the drug substance for Librela (bedinvetmab), a first in class monoclonal antibody used for treating osteoarthritis in dogs.   Launched in Europe, the UK and Switzerland, the product won ‘Best new companion animal product’ by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines suffering from this debilitating condition.   Syngene’s collaboration wi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters